Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zytiga in African American and Caucasian men with mCRPC
NCT01940276Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2013
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Duke University. Started Oct 2013; status: completed.
02
Drugs
abiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01940276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940276.